Protara Therapeutics (TARA) Current Deferred Revenue (2013)

Protara Therapeutics (TARA) recorded quarterly Current Deferred Revenue of $2.9 million in Q4 2013.

Protara Therapeutics (TARA) Current Deferred Revenue (2013) Analysis & Trends

Protara Therapeutics' Current Deferred Revenue history runs 1 years deep, the most recent figure standing at $2.9 million for Q4 2013.

In Q4 2013, Current Deferred Revenue changed N/A year-over-year to $2.9 million; the TTM figure through Dec 2013 stood at $2.9 million (changed N/A YoY), while the FY2013 annual figure was $2.9 million, changed N/A from the prior year.
Current Deferred Revenue was $2.9 million for Q4 2013 at Protara Therapeutics.
In the past five years, Current Deferred Revenue ranged from a high of $2.9 million in Q4 2013 to a low of $2.9 million in Q4 2013.

Peer Comparison

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Alterity Therapeutics	762,369.55 Bn	762,369.51 Bn	-
2	Belite Bio	55,096.00 Bn	55,096.00 Bn	-
3	Quantum Biopharma	17,755.80 Bn	17,755.79 Bn	-
4	Legend Biotech	3,486.00 Bn	3,485.71 Bn	242.10 Mn
5	Akari Therapeutics	1,737.42 Bn	1,737.41 Bn	-
6	Evaxion A	1,551.28 Bn	1,551.26 Bn	-
7	Psyence Biomedical	227.32 Bn	227.31 Bn	-
8	Vertex Pharmaceuticals	110.84 Bn	103.59 Bn	2.59 Bn
9	Abivax	91.71 Bn	91.71 Bn	-
10	Protara Therapeutics	216.35 Mn	216.35 Mn	-

Historic Data

Download Data

Date	Value
Dec 31, 2013	2.95 Mn